HDAC6 and cholangiocarcinoma: Treatment with an HDAC6 inhibitor such as Tubastatin-A increases the frequency of ciliated cholangiocarcinoma cells and decreases their proliferation, and ablation of cilia by disruption of key ciliogenesis gene Intraflagellar transport protein 88 (IFT88) abolishes this antiproliferative effect [22].